REPLIMUNE GROUP INC's ticker is REPL and the CUSIP is 76029N106. A total of 103 filers reported holding REPLIMUNE GROUP INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.5%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $78,334,371 | -26.3% | 4,578,280 | 0.0% | 0.45% | -26.7% |
| Q2 2023 | $106,307,662 | +31.5% | 4,578,280 | 0.0% | 0.62% | +39.8% |
| Q1 2023 | $80,852,425 | -35.1% | 4,578,280 | 0.0% | 0.44% | -41.2% |
| Q4 2022 | $124,529,216 | +85.2% | 4,578,280 | +17.6% | 0.75% | +70.0% |
| Q3 2022 | $67,247,000 | +7.1% | 3,893,843 | +8.4% | 0.44% | +23.6% |
| Q2 2022 | $62,772,000 | +129.4% | 3,591,081 | +122.8% | 0.36% | +126.8% |
| Q1 2022 | $27,367,000 | +70.2% | 1,611,703 | +171.6% | 0.16% | +101.3% |
| Q4 2021 | $16,081,000 | +253.4% | 593,395 | +286.5% | 0.08% | +290.0% |
| Q3 2021 | $4,550,000 | -22.9% | 153,512 | 0.0% | 0.02% | -23.1% |
| Q2 2021 | $5,898,000 | +25.9% | 153,512 | 0.0% | 0.03% | +30.0% |
| Q1 2021 | $4,684,000 | -20.0% | 153,512 | 0.0% | 0.02% | -9.1% |
| Q4 2020 | $5,856,000 | +23.1% | 153,512 | -25.7% | 0.02% | +15.8% |
| Q3 2020 | $4,756,000 | +3615.6% | 206,586 | +3918.4% | 0.02% | +1800.0% |
| Q2 2020 | $128,000 | – | 5,141 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Omega Fund Management, LLC | 4,673,380 | $81,691,000 | 26.08% |
| Atlas Venture Life Science Advisors, LLC | 3,209,627 | $56,104,000 | 9.38% |
| Redmile Group, LLC | 3,645,309 | $63,720,000 | 2.43% |
| Nan Fung Group Holdings Ltd | 155,199 | $2,713,000 | 1.86% |
| Frazier Life Sciences Management, L.P. | 806,267 | $14,094,000 | 1.33% |
| EMERALD MUTUAL FUND ADVISERS TRUST | 986,270 | $17,240,000 | 1.00% |
| EMERALD ADVISERS, LLC | 1,093,323 | $19,111,000 | 0.98% |
| Artal Group S.A. | 900,000 | $15,732,000 | 0.84% |
| Integral Health Asset Management, LLC | 219,194 | $3,832,000 | 0.79% |
| BVF INC/IL | 926,529 | $16,196,000 | 0.78% |